Investing Profile

Matias Serebrinsky(65)


Mental health and psychedelic therapeutics investor. Cofounder and GP at PsyMed Ventures.

psymed.venturesSan Francisco Bay Area
Photo of Matias Serebrinsky, General Partner at PsyMed Ventures

Signal uses Gmail to reveal intro paths. Email content is never read.

Sign in with Google →

4 Investors

Connected to Ariel Poler (Human Augmentation Syndicate), Brad Holden (TomorrowVentures), Michael Dempsey (Compound), and 1 other investor on Signal.

PsyMed Ventures General Partner
$100K - $2.5M
CompanyStageDateRound SizeTotal Raised
Delix Therapeutics
Series ASep 2021$70M
Co-investors: Vasudev Bailey (Artis Ventures (AV))
Seed+Sep 2021$250K
Journey Clinical
SeedAug 2021$250K
Pre-seedFeb 2021$150K
Beckley Psytech
Series BJun 2021$1
Co-investors: Amy Kruse (Prime Movers Lab), Kunal Sethi (Prithvi Ventures)
ATAI Life Sciences
Series DFeb 2021$3.6M
Series COct 2020$125M
Co-investors: Peter Thiel (Founders Fund), Stephen Hays (What If Ventures), Maryanna Saenko (Future Ventures), Akshay Sriprasad
Maya Health
SeedOct 2020$100K
Series ASep 2017$4M
Co-investors: Tim Chang (Mayfield), Matt Mullenweg (Audrey Capital), Ted Moskovitz
Investing in psychedelic medicine and tech that elevates health & wellness. Focus areas: -Psychedelics & New Compounds -Neurotech & BCI -Precision Psychiatry -Digital Therapeutics
Head of Inception (startup ecosystem) NVIDIA2016 - 2021
Cofounder CookUnity2014 - 2016